Breaking News
July 22, 2018 - Survey results identify major inequalities in acute stroke treatment across Europe
July 22, 2018 - Researchers discover promising treatment for genetic form of autism spectrum disorder
July 22, 2018 - Prenatal Depression More Common in Young Moms Today
July 22, 2018 - What helps adults with autism get and keep a job?
July 22, 2018 - Pediatric NEXUS Head CT DI guides selective imaging decisions in blunt trauma patients
July 22, 2018 - Novel tool predicts genes that cause disease due to production of truncated proteins
July 22, 2018 - AHA: Vaping Tied to Blood Clots — in Mice
July 22, 2018 - Study finds therapy dogs effective in reducing symptoms of ADHD
July 22, 2018 - Scientists find reason why malarial parasites are faster than immune cells
July 22, 2018 - Researchers gain more insight into how FUS protein causes ALS and FTLD
July 22, 2018 - Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
July 22, 2018 - QUT researcher highlights growing impact of non-prescription antibiotics supply in pharmacies
July 22, 2018 - UK health communication researcher seeks solutions for disposing leftover medicine
July 22, 2018 - Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
July 22, 2018 - Mutation discovered to protect against Alzheimer’s disease in mice
July 22, 2018 - Researchers reveal how patients in urban areas develop multiple, long-term conditions
July 22, 2018 - Replacing conventional cancer treatment with complementary therapy linked to increased risk of death
July 22, 2018 - Study uncovers molecular key for delaying progression of multiple sclerosis
July 22, 2018 - Availability of athletic trainer in high school reduces injury rates in girls’ sports, shows study
July 22, 2018 - FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
July 22, 2018 - Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
July 22, 2018 - Physical activity even during exposure to air pollution can reduce risk of heart attack
July 22, 2018 - Scientists discover protein regulator of myelin production
July 22, 2018 - Sleep disturbances associated with higher dementia risk
July 22, 2018 - Scientists move one step further in developing eye drops to treat age-related macular degeneration
July 22, 2018 - Five-Year Stroke Rates Lower After PCI Versus CABG
July 21, 2018 - Alopecia areata – Genetics Home Reference
July 21, 2018 - Study identifies overdose risk factors in youth with substance use disorders
July 21, 2018 - Drug in clinical trials for Parkinson’s disease offers hope for treating heart failure
July 21, 2018 - Coupling free malaria tests with diagnosis-dependent vouchers can improve rational use of ACTs
July 21, 2018 - Sweetness depends on molecular interactions between specific sugars and water in saliva
July 21, 2018 - Muscle fitness is strongly associated with improved rate of ageing in the brain
July 21, 2018 - Resetting E-Prescriptions for Opioids Helps Curb Use: Study
July 21, 2018 - Overuse of antibiotics not what the doctor ordered
July 21, 2018 - Bundled-payment system did not lower costs for serious medical conditions, shows study
July 21, 2018 - Therapy dogs found to be effective in reducing ADHD symptoms in children
July 21, 2018 - Could rotating multiple therapists better treat PTSD patients?
July 21, 2018 - Binge drinking impairs working memory in adolescent brain
July 21, 2018 - Dying at home could be beneficial for terminally ill cancer patients and their relatives
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Using tendon transfer surgery to restore key functions in spinal cord injury patient
July 21, 2018 - Scientists create wearable device that measures cortisol in sweat
July 21, 2018 - Researchers study efficacy and safety of new treatment for OUD
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
FDA and Opioids: Too Much Regulation or Not Enough?

FDA and Opioids: Too Much Regulation or Not Enough?

image_pdfDownload PDFimage_print

SILVER SPRING, Md. — If the FDA is looking for a streamlined approach to respond to the opioid crisis, it didn’t come from a public meeting of the agency’s Opioid Policy Steering Committee.

At the meeting Tuesday, academics, physicians, patients, advocates, and industry officials shared sometimes conflicting recommendations on how the FDA can best handle the problem.

Advocates generally fell into two camps: pain patients and their supporters, concerned that opioids are being over-regulated and becoming harder to access, and people who have lost loved ones to addiction and overdoses, and would like to see stronger restrictions on such products.

Meanwhile, healthcare experts stressed addiction and overdose prevention, better provider education and awareness efforts, and the elimination of “doctor-shopping.”

In September 2017, the FDA issued a request for comment, which said the national crisis is one that requires “action by federal agencies that may in some instances be unprecedented.” The notice solicited public input to help the agency determine what it should leverage to respond to the crisis.

President Trump declared the opioid epidemic a public health emergency a month later. Approximately 64,000 people died from opioid overdoses in 2016.

The FDA notice included a handful of direct questions for stakeholders, such as:

  • How can the agency use the available public health data to influence opioid related regulatory decisions?
  • What changes can the agency make with regard to “dispensing and packaging” to encourage proper prescribing practices?
  • Should mandatory education be required for clinicians who prescribe opioids?

At the recent meeting, agency officials also discussed whether to specify dose limits, the creation of a nationwide prescription history database, and how to assess the impact of prescription drug monitoring programs (PDMP).

With regard to provider education, “there is no evidence, in the published literature, that mandatory education increases knowledge or changes behavior and practice,” pointed out Norman Kahn, MD, of the Conjoint Committee on Continuing Education. “If the goal is to count the number of people who complete the education, then of course we should make it mandatory.”

“If … the goal is to make people learn and change the behavior and practice, that doesn’t happen with mandatory education. That happens with voluntary education,” he stressed.

Kahn said he has discussed the idea of an “adaptive learning” approach with the Centers for Medicare and Medicaid Services. He said he has hopes that such an approach might count as an improvement program under the Merit-Based Incentive Payment System (MIPS).

Another concern is the language used to describe opioids, stated Diana Zuckerman, PhD, of the National Center for Health Research. She said “abuse deterrent” may mean different things to doctors, patients, and family members.

She urged the FDA to include education on the meaning of “abuse deterrent” within its Risk Evaluation and Mitigation Strategies (REMS) because “too often it’s misinterpreted to mean it’s not as addictive.”

But Zuckerman also questioned the value of REMS itself, claiming that the “vast majority” of physicians don’t even know REMS exists. Following the implementation of REMS, one prescriber-based survey found 48% of respondents said they did not change their prescribing habits, she noted. Also, while 49% said they made use of the patient counseling documents, that means roughly half did not, she added.

On the advocates’ side, Richard Lawhern, PhD, co-founder of the Alliance for the Treatment of Intractable Pain, urged the FDA to “stand down” from additional regulations on opioids.

He said that the agency is chasing the wrong crisis, as more regulation “is going to make the real crisis worse,” by driving patients into the realm of heroin and/or other illegal street drugs. He also urged the FDA to “remove and rewrite” its practice standards regarding opioids, and he dismissed the Centers for Disease Control and Prevention’s revised guidelines as “nonsense.”

Emily Walden, of Louisville, Kentucky, called on the FDA to remove the highest dose opioids from the market and “immediately delay any new approvals.” Her 22-year-old son died because of an opioid addiction, she said.

She also pressed the agency to end its use of enriched enrollment in clinical trial design. The FDA describes the method as a way to “increase the likelihood that data collected during a clinical trial will demonstrate that an effective drug is effective.”

Other topics discussed at the meeting included the need to increase e-prescribing, improve PDMP, and integrate both into electronic health records (EHR) systems.

Robert Heary, MD, of the American Association of Neurological Surgeons, suggested providers complete a short (less than 5 minutes), standardized form, with each opioid prescription, to explain why the prescription is medically justified. If a national PDMP were established, data from those forms could feed into it and be cross-checked at the pharmacy.

He noted that having a connected PDMP would prevent doctor-shopping across state lines.

Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research called it a “bold proposal,” but questioned how much of a burden these additional measures would be for providers.

Patrice Harris, MD, an American Medical Association trustee and chair of the AMA’s Opioid Task Force expressed skepticism about the capacity of today’s EHRs. Recommendations on e-prescribing “overstate and overestimate the current capabilities of today’s electronic systems,” she said, adding that e-prescribing “in its current state” may not be suited to “explain medical necessity.”

While physicians may prefer e-prescribing, the pin numbers, passwords, and authentication processes can be “onerous” and may take time away from direct patient care, she added.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles